Marks & Clerk, one of the world’s leading intellectual property (IP) law firms, has announced the promotion of Andrea Williams to Partner and the appointment of Senior Associate David Kemp to the Cambridge team, transferring from the London office. Both attorneys are part of the firm’s market-leading UK teams, with Andrea specialising in patents in the biotechnology field and David advising on all aspects of UK, EUTM and international trade mark law and practice. “I am delighted to announce the promotion of Andrea Williams to Partner, and welcome David Kemp to Cambridge. The attorneys in…
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR ANNOUNCES AN EXCLUSIVE FORMULATION STUDY COLLABORATION WITH
A LEADING GLOBAL MEDICAL PRODUCTS COMPANY TO DEVELOP A STABLE READY TO ADMINISTER PRODUCT
Cambridge, UK, 1 November 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed an exclusive formulation study collaboration with a leading global medical products company.
Under the terms of the agreement, Arecor will use its proprietary formulation technology platform, Arestat™, to…
Closed Loop Medicine has closed £13 million GBP (c. $17million USD) of new investment from a range of top UK and European venture capital investors. The money has been raised to finance its personalised drug + digital therapy (DTx) combination products which are being developed to improve outcomes for patients and clinicians through precision dosing.
Round led by Ananda Impact Ventures and BGF, joined by a strong syndicate of investors including LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels.The financing was oversubscribedInvestment will fund further platform…
This is the second time writing about the Neurim v Mylan battle “take two” concerning a divisional patent (EP 3 103 443) granted on 30 June 2021 (but expires 12 August 2022). The first article (Neurim v Mylan: Take Two) covered Neurim’s successful application for an expedited preliminary issue trial. That article also covers (some of) the twists and turns of the original Neurim v Mylan battle on the parent patent.
October brought Mylan’s opportunity to convince the Patents Court (Ian Karet sitting as a Deputy High Court Judge) to stay the UK proceedings pending final determination of the…
CAMBRIDGE, United Kingdom, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionizing genome sequencing, today announced the signing of an $88 million Series D financing, bringing the total funds raised to date to $146 million. Temasek led the Series D round with participation from new investors including Third Point and existing investors such as GV, New Science Ventures, Ahren Innovation Capital and Sequoia.
Proceeds from the financing will be used to commercialize the company’s proprietary genetic and epigenetic sequencing…
Cambridge, UK, 02 November 2021: Mogrify Limited (Mogrify®), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as an independent member of the Board of Directors. Tom is a seasoned financial executive bringing a wealth of global experience that spans corporate…
Commenting in reaction to the Chancellor’s budget on 27th October 2021, Dr Peter Jackson, executive director, Infex Therapeutics, said:
“The announcement today that the government is increasing public R&D investment to record levels to cement the UK as a global science and technology superpower is hugely encouraging news, and reflects the importance of innovative, entrepreneurial companies to the future economic wellbeing of our country as we seek to recover from the pandemic.
“In particular it is very encouraging to see funding for Innovate UK increasing significantly to £1.1 billion by…
"Diagnostics - More important than ever, but there's still a way to go".
Diagnostics are clearly improving and enabling better clinical decisions to be made, especially in oncology where mutation detection is enabling much more personalised approaches to treatment. There is still a long way to go, but combinations of diagnostics tests and technologies (beyond genomics) are giving a more detailed picture on which to base treatment decisions.
Just the other week, it was announced that Illumina had acquired GRAIL (subject to approval from the regulators), a company itformed in 2016 and…
Oxford, UK, Friday 15th October: PharmaVentures is pleased to announce that it acted as the lead advisor to IntoCell on its new research collaboration with Ab Studio. This follows the recent announcement that IntoCell has established a research collaboration partnership with Ab Studio to develop antibody drug conjugate (ADC) using IntoCell’s proprietary PMT payloads and Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker technology, and a novel internalizing antibody from Ab Studio. Steve Waterman, Managing Director at PharmaVentures, said “We are pleased to have assisted IntoCell…